- Home
- ENVB vs SLRX Comparison
ENVB vs SLRX Comparison
Compare ENVB & SLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENVB
- SLRX
- Stock Information
- Founded
- ENVB 1994
- SLRX N/A
- Country
- ENVB United States
- SLRX United States
- Employees
- ENVB N/A
- SLRX N/A
- Industry
- ENVB Biotechnology: Pharmaceutical Preparations
- SLRX Biotechnology: Pharmaceutical Preparations
- Sector
- ENVB Health Care
- SLRX Health Care
- Exchange
- ENVB Nasdaq
- SLRX Nasdaq
- Market Cap
- ENVB 3.0M
- SLRX 3.6M
- IPO Year
- ENVB N/A
- SLRX N/A
- Fundamental
- Price
- ENVB $5.63
- SLRX $0.84
- Analyst Decision
- ENVB Strong Buy
- SLRX
- Analyst Count
- ENVB 1
- SLRX 0
- Target Price
- ENVB $120.00
- SLRX N/A
- AVG Volume (30 Days)
- ENVB 128.8K
- SLRX 1.6M
- Earning Date
- ENVB 11-14-2025
- SLRX 11-14-2025
- Dividend Yield
- ENVB N/A
- SLRX N/A
- EPS Growth
- ENVB N/A
- SLRX N/A
- EPS
- ENVB N/A
- SLRX N/A
- Revenue
- ENVB N/A
- SLRX N/A
- Revenue This Year
- ENVB N/A
- SLRX N/A
- Revenue Next Year
- ENVB N/A
- SLRX N/A
- P/E Ratio
- ENVB N/A
- SLRX N/A
- Revenue Growth
- ENVB N/A
- SLRX N/A
- 52 Week Low
- ENVB $4.88
- SLRX $0.83
- 52 Week High
- ENVB $96.30
- SLRX $1.29
- Technical
- Relative Strength Index (RSI)
- ENVB 59.55
- SLRX 20.86
- Support Level
- ENVB $4.88
- SLRX $1.10
- Resistance Level
- ENVB $6.10
- SLRX $1.29
- Average True Range (ATR)
- ENVB 0.90
- SLRX 0.39
- MACD
- ENVB -0.19
- SLRX -0.22
- Stochastic Oscillator
- ENVB 20.64
- SLRX 0.72
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.
About SLRX Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.